SCHEMBL10135119

SCHEMBL10135119

Nc1ncc(Nc2cccnc2)nc1-c1nc2ccccc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 12/20 0.64
KDM4E B2RXH2 2/20 0.49
LDHA P00338 1/20 0.49
EPHX2 P34913 1/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
CDK1 P06493 1/20 0.47
CDK2 P24941 1/20 0.47
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
PRKDC P78527 1/20 0.46
ATM Q13315 1/20 0.46
METAP2 P50579 1/20 0.45
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
WNT1 P04628 1/20 0.44
TGFBR1 P36897 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054972 0.78 ATR (1.00) ATRKDM4ELDHAEPHX2PRKDC
SCHEMBL560058 0.75 ATR (0.64) ATRKDM4ELDHAEPHX2CDK1
SCHEMBL559735 0.74 ATR (0.60) ATRKDM4EMEN1KMT2ACDK1
SCHEMBL560241 0.73 ATR (0.68) ATRKDM4ENPC1RAB9ACDK1
SCHEMBL13354021 0.72 ATR (0.67) ATRKDM4ENPC1RAB9ACDK1
SCHEMBL1163512 0.72 KMT2A (0.59) KDM4ELDHAEPHX2NPC1RAB9A
SCHEMBL1900530 0.72 CDK1 (0.65) ATRKDM4ENPC1RAB9ACDK1
SCHEMBL2484717 0.70 ATR (1.00) ATRCDK1CDK2MKNK1MKNK2
SCHEMBL560251 0.69 ATR (0.64) ATRKDM4ENPC1RAB9ACDK1
SCHEMBL2681176 0.68 CDK1 (0.79) ATRKDM4ELDHAEPHX2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ATR 1/4885KDM4E 2074/4885LDHA 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.